Publications by authors named "Karen McBride"
Aims: At the time of the design of the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study in 1996, oral hormone therapy (HT) was assumed to reduce cardiovascular risk. The evidence mainly came from the effects of combined conjugated equine oestrogens plus medroxyprogesterone acetate (CEE/MPA) therapy. Other HT regimes had not been studied widely.
View Article and Find Full Text PDFAims: To estimate the degree of under-reporting of diabetes on death certificates, and to describe the population of patients enrolled on the Otago Diabetes Register known to have died during the 6-year period to 31 December 2003.
Methods: The Otago Diabetes Register was established in 1998, as part of the Otago Diabetes Project, to monitor and evaluate diabetes care in the Otago region, New Zealand. Demographic and clinical data, including vital status, type of diabetes and year of diagnosis, diabetes complications, diabetes medication and clinical examination, and biochemistry test results were collected annually from general practice medical records.
The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) trial is a three-arm, randomized, placebo-controlled, double-blind study to determine the effect of tibolone 2.5 mg (Org OD 14) and continuous combined conjugated equine estrogens plus medroxyprogesterone acetate (0.625 mg/2.
View Article and Find Full Text PDFObjective: To examine if delayed transfer to the intensive care unit (ICU) after physiologic deterioration is associated with increased morbidity and mortality.
Design: Inception cohort.
Setting: Community hospital in Ogden, Utah.